Relevance of Patient-reported Outcomes for the Management of Patients with Inflammatory Bowel Disease

Disclosure: Prof Dr Axel Dignass has received grants/research support from the Institut für Gemeinwohl and Stiftung Leben mit Krebs, and honoraria or consultation fees from AbbVie, MSD, Ferring, Roche/Genentech, Takeda, Pharmacosmos, Holystone Biotech, Falk, Mundipharma, Toray, Allergosan, Hospira, Robarts, TFS Trial Support, and Sandoz/Hexal. He has participated in company-sponsored speaker’s bureaus for the Falk Foundation, Ferring, MSD, AbbVie, Otsuka, Vifor, Immundiagnostik, Janssen-Cilag, Med Update GmbH, Medice, CED Service GmbH, and Mundipharma. He has received payment for manuscript preparation from the Falk Foundation, Wiley, and Thieme, and payment for educational presentations from Pharmacosmos, the Falk Foundation, Ferring, Takeda, and Tillotts Pharma AG. Acknowledgements: Writing assistance was provided by Morgan McKenzie of Ashfield Healthcare Communications Ltd. Support: The publication of this article was funded by Tillotts Pharma AG. The webinar was an independent educational event sponsored by Tillotts Pharma AG, and the views and opinions expressed are those of the speakers and not necessarily of Tillotts Pharma AG. Tillotts Pharma AG had no influence over the content of this article or the webinar on which it was based. Citation: EMJ Gastroenterol. 2016;5[1]:43-48.